Advanced search
Publication Cover
Leukemia & Lymphoma Volume 49, 2008 - Issue 7
Submit an article Journal homepage
98
Views
19
CrossRef citations to date
0
Altmetric
Letters to the Editor

Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha

Dushyant Verma Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
,
Hagop Kantarjian Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
,
Nitin Jain Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
&
Jorge Cortes Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
Pages 1399-1402 | Received 04 Mar 2008, Accepted 08 Mar 2008, Published online: 01 Jul 2009

Citations (19)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Amir Imran Faisal Hamdi, Soon Hin How, Mohammad Kaisarul Islam, Jonathan Chee Woei Lim & Johnson Stanslas. (2022) Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?. Expert Review of Anticancer Therapy 22:12, pages 1309-1323.
Read now
Hyun-Gyung Goh, Yoo-Jin Kim, Dong-Wook Kim$suffix/text()$suffix/text(), Hyeoung-Joon Kim, Soo-Hyun Kim, Se-Eun Jang, Jeong Lee, Dongho Kim, Wan-Seok Kim, Sa-Hee Park & Il-Young Kweon. (2009) Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy. Leukemia & Lymphoma 50:6, pages 944-951.
Read now
David M. Ross & Timothy P. Hughes. (2008) How complete is “complete” molecular response in imatinib-treated chronic myeloid leukemia?. Leukemia & Lymphoma 49:7, pages 1230-1231.
Read now

Articles from other publishers (16)

Zhanet Grudeva-Popova, Emil Spasov, Vasko Graklanov, Katya Sotirova, Veselin Popov, Gueorgui Balatzenko & Ivanka Hristova. (2019) Are Successful Pregnancies an Achievable Goal in Patients with Chronic Myeloid Leukaemia?. EMJ Hematology, pages 80-84.
Crossref
Srinivas K. Tantravahi, Raga S. Guthula, Thomas O’Hare & Michael W. Deininger. (2017) Minimal Residual Disease Eradication in CML: Does It Really Matter?. Current Hematologic Malignancy Reports 12:5, pages 495-505.
Crossref
Simona Soverini, Caterina De Benedittis, Manuela Mancini & Giovanni Martinelli. (2016) Present and future of molecular monitoring in chronic myeloid leukaemia. British Journal of Haematology 173:3, pages 337-349.
Crossref
David M. Ross & Timothy P. Hughes. (2014) How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia. British Journal of Haematology 166:1, pages 3-11.
Crossref
Simona Soverini, Gianantonio Rosti, Michele Baccarani & Giovanni Martinelli. (2014) Molecular Monitoring. Current Hematologic Malignancy Reports 9:1, pages 1-8.
Crossref
Kendra Sweet & Vivian Oehler. (2013) Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when is this a safe option to consider?. Hematology 2013:1, pages 184-188.
Crossref
Michael J. Mauro. (2013) Striving to achieve safe, permanent treatment discontinuation in chronic myeloid leukemia. Leukemia Research 37:11, pages 1395-1403.
Crossref
David M. RossSusan BranfordJohn F. SeymourAnthony P. SchwarerChristopher ArthurDavid T. YeungPhuong DangJarrad M. GoyneCassandra SladerRobin J. FilshieAnthony K. Mills, Junia V. MeloDeborah L. WhiteAndrew P. Grigg & Timothy P. Hughes. (2013) Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122:4, pages 515-522.
Crossref
Sung‐Eun Lee, Soo Young Choi, Ju‐Hee Bang, Soo‐Hyun Kim, Eun‐jung Jang, Ji‐Young Byeun, Jin‐Eok Park, Hye‐Rim Jeon, Yun Jeong Oh, Hyeoung‐Joon Kim, Yeo‐Kyeoung Kim, Joon Seong Park, Seong Hyun Jeong, Sung‐Hyun Kim, Dae Young Zang, Sukjoong Oh, Dong Hoe Koo, Hawk Kim, Young Rok Do, Jae‐Yong Kwak, Jeong‐A Kim, Dae‐Young Kim, Yeung‐Chul Mun, Michael J. Mauro & Dong‐Wook Kim. (2013) Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib. American Journal of Hematology 88:6, pages 449-454.
Crossref
François-Xavier Mahon. (2012) Is going for cure in chronic myeloid leukemia possible and justifiable?. Hematology 2012:1, pages 122-128.
Crossref
Jean-Claude Chomel & Ali G. Turhan. (2011) Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. Oncotarget 2:9, pages 713-727.
Crossref
D M Ross, T P Hughes & J V Melo. (2010) Do we have to kill the last CML cell?. Leukemia 25:2, pages 193-200.
Crossref
François-Xavier Mahon, Delphine Réa, Joëlle Guilhot, François Guilhot, Françoise Huguet, Franck Nicolini, Laurence Legros, Aude Charbonnier, Agnès Guerci, Bruno Varet, Gabriel Etienne, Josy Reiffers & Philippe Rousselot. (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. The Lancet Oncology 11:11, pages 1029-1035.
Crossref
Alfonso Quintás-Cardama, Hagop Kantarjian & Jorge Cortes. (2009) Imatinib and beyond—exploring the full potential of targeted therapy for CML. Nature Reviews Clinical Oncology 6:9, pages 535-543.
Crossref
Salvatore Guastafierro, Umberto Falcone, Maria Celentano, Milena Coppola, Maria Giovanna Ferrara & Antonello Sica. (2009) Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature. Leukemia Research 33:8, pages 1079-1081.
Crossref
Juan-Carlos Hernández-Boluda, María Collado, Desamparados Roda, Paula Amat, Mar Tormo & Isabel Marugán. (2009) Sustained complete molecular remission after imatinib discontinuation due to severe aplastic anemia. Leukemia Research 33:4, pages 589-592.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.